NCT00388362View on ClinicalTrials.gov

Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

November 30, 2010

Study Completion Date

August 31, 2012

Conditions
Graft vs Host Disease
Interventions
DRUG

Sirolimus

Patients will receive sirolimus at 2 mg/day orally with monitoring of trough drug levels weekly for 2 weeks to achieve trough drug levels 7-12 ng/ml. Along with prednisone therapy.

DRUG

Prednisone

Prednisone therapy will remain at the dose the patient received at the time sirolimus was begun. Withdrawal of prednisone will began after first evidence of improvement of chronic GVHD.

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

All Listed Sponsors
lead

Stanford University

OTHER

NCT00388362 - Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease | Biotech Hunter | Biotech Hunter